ELYM stock icon

Eliem Therapeutics
ELYM

$7.17
5.28%
 

About: Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).

Employees: 11

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

2% more capital invested

Capital invested by funds: $45.5M [Q4 2023] → $46.2M (+$689K) [Q1 2024]

0.01% more ownership

Funds ownership: 61.13% [Q4 2023] → 61.14% (+0.01%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

9% less funds holding

Funds holding: 23 [Q4 2023] → 21 (-2) [Q1 2024]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for ELYM.

Financial journalist opinion